Caribou Biosciences (CRBU) Revenue & Revenue Breakdown
Caribou Biosciences Revenue Highlights
Latest Revenue (Y)
$34.48M
Latest Revenue (Q)
$3.46M
Main Geography (Y)
UNITED STATES
Caribou Biosciences Revenue by Period
Caribou Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $34.48M | 148.91% |
| 2022-12-31 | $13.85M | 44.31% |
| 2021-12-31 | $9.60M | -22.35% |
| 2020-12-31 | $12.36M | 113.56% |
| 2019-12-31 | $5.79M | - |
Caribou Biosciences generated $34.48M in revenue during NA 2023, up 148.91% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Caribou Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $3.46M | 42.61% |
| 2024-03-31 | $2.43M | -31.73% |
| 2023-12-31 | $3.56M | -84.96% |
| 2023-09-30 | $23.66M | 530.15% |
| 2023-06-30 | $3.75M | 7.22% |
| 2023-03-31 | $3.50M | -5.15% |
| 2022-12-31 | $3.69M | 11.78% |
| 2022-09-30 | $3.30M | -21.21% |
| 2022-06-30 | $4.19M | 57.36% |
| 2022-03-31 | $2.66M | 4.10% |
| 2021-12-31 | $2.56M | -35.66% |
| 2021-09-30 | $3.98M | 169.44% |
| 2021-06-30 | $1.48M | -6.94% |
| 2021-03-31 | $1.59M | 61.18% |
| 2020-12-31 | $984.00K | -17.86% |
| 2020-09-30 | $1.20M | -85.87% |
| 2020-06-30 | $8.48M | 398.41% |
| 2020-03-31 | $1.70M | - |
Caribou Biosciences generated $3.46M in revenue during Q2 2024, up 42.61% compared to the previous quarter, and up 98.91% compared to the same period a year ago.
Caribou Biosciences Revenue Breakdown
Caribou Biosciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Non-US | $1.71M | $548.00K | $685.00K |
| UNITED STATES | $32.77M | $13.30M | $8.91M |
Caribou Biosciences's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (95.05%), and Non-US (4.95%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $2.27M | $2.35M | $3.75M | $3.38M | $3.54M | $2.97M | $4.18M | $2.61M | $2.43M | $3.51M | $1.48M |
| Non-US | $160.00K | $1.20M | $9.00K | $117.00K | $150.00K | $337.00K | $9.00K | $52.00K | $129.00K | - | - |
| Non Us | - | - | - | - | - | - | - | - | - | $470.00K | $111.00K |
Caribou Biosciences's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (93.41%), and Non-US (6.59%).
Caribou Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| ADPT | Adaptive Bio | $170.28M | $43.19M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| SANA | Sana Bio | - | - |
CRBU Revenue FAQ
What is Caribou Biosciences’s yearly revenue?
Caribou Biosciences's yearly revenue for 2023 was $34.48M, representing an increase of 148.91% compared to 2022. The company's yearly revenue for 2022 was $13.85M, representing an increase of 44.31% compared to 2021. CRBU's yearly revenue for 2021 was $9.6M, representing a decrease of -22.35% compared to 2020.
What is Caribou Biosciences’s quarterly revenue?
Caribou Biosciences's quarterly revenue for Q2 2024 was $3.46M, a 42.61% increase from the previous quarter (Q1 2024), and a -7.75% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.43M, a -31.73% decrease from the previous quarter (Q4 2023), and a -30.64% decrease year-over-year (Q1 2023). CRBU's quarterly revenue for Q4 2023 was $3.56M, a -84.96% decrease from the previous quarter (Q3 2023), and a -3.63% decrease year-over-year (Q4 2022).
What is Caribou Biosciences’s revenue growth rate?
Caribou Biosciences's revenue growth rate for the last 3 years (2021-2023) was 259.21%, and for the last 5 years (2019-2023) was 495.66%.